CFDE Data Portal | Search RN7SL709P

	Label	Description
	RN7SL709P Gene (Entity type)	ENSG00000241032 - RNA, 7SL, cytoplasmic 709, pseudogene
	GSE48812 sulforaphane 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE149632 dopamine 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE164874 prednisolone muscle organ 5 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE153354 TCF19 knockout CAL-27 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE210476 rutaecarpine macrophage 2 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE115328 lenalidomide 6 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE206959 reserpine 2 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158738 azacitidine 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE79027 L-13 3 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS

RN7SL709P

ENSG00000241032 - RNA, 7SL, cytoplasmic 709, pseudogene

GSE48812 sulforaphane 2 v 5 human up

A Gene Set from LINCS

GSE149632 dopamine 0 v 6 human up

A Gene Set from LINCS

GSE164874 prednisolone muscle organ 5 v 1 human dn

A Gene Set from LINCS

GSE153354 TCF19 knockout CAL-27 0 v 1 human dn

A Gene Set from LINCS

GSE210476 rutaecarpine macrophage 2 v 7 human dn

A Gene Set from LINCS

GSE115328 lenalidomide 6 v 0 human dn

A Gene Set from LINCS

GSE206959 reserpine 2 v 3 human dn

A Gene Set from LINCS

GSE158738 azacitidine 0 v 1 human dn

A Gene Set from LINCS

GSE79027 L-13 3 v 6 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.